Scandion Oncology

Stockholm: SCOL

Market CapSEK514m

Last Close SEK16

Scandion Oncology is a biotechnology company focused on developing therapeutics to counter drug resistance in cancer.

More Scandion Oncology content >

Investment summary

Scandion Oncology is a biotechnology company focused on the development of therapies to alleviate drug resistance in prevalent cancers. Its most advanced clinical asset, SCO-101, acts via a dual mechanism to sensitise resistant cells to treatment. Scandion aims to target resistant metastatic colorectal cancer (mCRC) and pancreatic cancer with SCO-101. Part 1 of the Phase II trial, CORIST, in mCRC identified a tolerated dose and a good safety profile in July 2021. The proof-of-concept part 2 study is underway. Results from the CORIST and Phase Ib trial, PANTAX, in pancreatic cancer are both expected in Q2–Q322.

Content on Scandion Oncology
Scandion Oncology – Drug-resistant cancer solutions
Healthcare | research QuickView | 14 January 2022
Edison QuickView
View more
Register to receive research on Scandion Oncology as it is published
Share price graph
Price performance
Actual (5.9) 21.2 (13.4)
Relative* 0.7 26.1 (3.3)
52-week high/low SEK20.7/SEK11.8
*% relative to local index